Evidence map›Paper›PMID 30829533›Full record

ArticleAIDS care2019

Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.

Martha Shumway, Anne F Luetkemeyer, Marion G Peters, Mallory O Johnson, Tessa M Napoles, Elise D Riley

Abstract read
In one paragraph

Article in AIDS care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Martha ShumwayDepartment of Psychiatry, Weill Institute for Neurosciences, University of California , San Francisco , CA , USA.
Anne F LuetkemeyerDepartment of Medicine, University of California , San Francisco , CA , USA.
Marion G PetersDepartment of Medicine, University of California , San Francisco , CA , USA.
Mallory O JohnsonDepartment of Medicine, University of California , San Francisco , CA , USA.
Tessa M NapolesDepartment of Medicine, University of California , San Francisco , CA , USA.
Elise D RileyDepartment of Medicine, University of California , San Francisco , CA , USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
UCSF HIV Clinical Trials UnitUM1AI069502 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2012 to 2013
$10.3M
Mentoring patient-oriented research on the health consequences of polydrug useK24DA039780 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RILEY, ELISE D. · 2015 to 2025
$1.9M
Mentoring and Empowerment in the Context of HIV Care for At-Risk PopulationsK24DA037034 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSON, MALLORY O · 2014 to 2018
$918k
NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI069502NIAID NIH HHS UM1 AI106701NIDA NIH HHS K24 DA037034NIDA NIH HHS K24 DA039780NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

HIV/HCV coinfected patients are a priority for direct acting antiretroviral (DAA) treatment, yet barriers to treating vulnerable patients persist. This study surveyed safety net clinic patients and providers to quantify their preferences for DAA treatment and prioritize modifiable barriers. Preferences were assessed using best-worst scaling. General linear mixed models were used to determine whether attributes differed in importance and whether patients and providers valued attributes differently. 158 HIV/HCV coinfected patients and 49 providers participated. Patients and providers had strong preferences for treatment within the medical homes where patients receive HIV care. Support such as reminders and advice numbers were also important, but were more important to providers than patients. Providers identified lack of insurance coverage for DAA as the most significant barrier. Providers rated HIV primary care providers as best suited to deliver DAA to HIV+ patients. Addressing structural barriers is essential for increasing DAA treatment in safety net settings.

Indexed as

Patient PreferencePhysician-Patient RelationsAdultAntiviral AgentsFemaleHepatitis C, ChronicHIV InfectionsHumansMaleMiddle AgedSan FranciscoTreatment OutcomeAntiviral Agentscoinfectiondirect-acting antiviralshepatitis CHIVpreferencesvulnerable populations

Identifiers

PMID30829533
PMCPMC6722022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.